Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2006; 48:914-923, doi:10.1016/j.jacc.2006.04.086 (Published online 14 August 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2006.04.086v1
48/5/914    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaul, S.
Right arrow Articles by Shah, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaul, S.
Right arrow Articles by Shah, P. K.

STATE-OF-THE-ART PAPER

Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease

Not Validated

Sanjay Kaul, MD*,{dagger},*, Andrew A. Zadeh, MD*,{dagger} and Prediman K. Shah, MD*,{dagger}

* Division of Cardiology, Cedars-Sinai Medical Center
{dagger} David Geffen School of Medicine, University of California, Los Angeles, California Drs. Kaul and Zadeh contributed equally to this work.

Manuscript received January 24, 2006; revised manuscript received March 28, 2006, accepted April 4, 2006.

* Reprint requests and correspondence: Dr. Sanjay Kaul, Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048 (Email: kaul{at}cshs.org).

Homocysteine has been implicated in promoting atherosclerotic and thrombotic vascular disease. During the last decade, the utility of homocysteine in predicting risk for atherothrombotic vascular disease has been evaluated in several observational studies in a large number of patients. These studies show that the overall risk for vascular disease is small, with prospective, longitudinal studies reporting a weaker association between homocysteine and atherothrombotic vascular disease compared to retrospective case-control and cross-sectional studies. Furthermore, randomized controlled trials of homocysteine-lowering therapy have failed to prove a causal relationship. On the basis of these results, there is currently insufficient evidence to recommend routine screening and treatment of elevated homocysteine concentrations with folic acid and other vitamins to prevent atherothrombotic vascular disease. This review outlines the metabolism and pathophysiology of homocysteine, highlights the results of homocysteine observational and interventional trials, and presents areas of uncertainty and potential future work.

Abbreviations and Acronyms
  CAD = coronary artery disease
  CVD = cardiovascular disease
  HOPE-2 = Heart Outcomes Prevention Evaluation-2 trial
  IHD = ischemic heart disease
  MACE = major adverse cardiac event
  MI = myocardial infarction
  MTHFR = methylene tetrahydrofolate reductase
  NORVIT = Norwegian Vitamin Trial
  tHcy = total homocysteine
  VISP = Vitamin Intervention for Stroke Prevention study




This article has been cited by other articles:


Home page
StrokeHome page
T. Jax and T. Lauer
The Art of Primary Prevention and Risk Assessment: Homocysteine Revisited
Stroke, March 1, 2009; 40(3): 670 - 671.
[Full Text] [PDF]


Home page
Diabetes CareHome page
S. G. Bruce and T. K. Young
Prevalence and Risk Factors for Neuropathy in a Canadian First Nation Community
Diabetes Care, September 1, 2008; 31(9): 1837 - 1841.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. S. Getz and C. A. Reardon
Nutrition and Cardiovascular Disease
Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2499 - 2506.
[Abstract] [Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
A. S Wierzbicki
Homocysteine and cardiovascular disease: a review of the evidence
Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 143 - 149.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
S. Kaul, A. A. Zadeh, and P. K. Shah
Reply
J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1371 - 1371.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. Akhtar
Is Homocysteine a Risk Factor for Atherothrombotic Cardiovascular Disease?
J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1370 - 1371.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. M. Wilson, R. B. McCaw, L. Leo, E. Arning, S. Lhotak, T. Bottiglieri, R. C. Austin, and S. R. Lentz
Prothrombotic Effects of Hyperhomocysteinemia and Hypercholesterolemia in ApoE-Deficient Mice
Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 233 - 240.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement